Celldex Therapeutics, Inc. $CLDX Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. lowered its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 41.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,146 shares of the biopharmaceutical company’s stock after selling 13,524 shares during the period. Fox Run Management L.L.C.’s holdings in Celldex Therapeutics were worth $390,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Nuveen LLC purchased a new position in Celldex Therapeutics during the 1st quarter worth $7,789,000. Millennium Management LLC increased its holdings in Celldex Therapeutics by 327.3% in the first quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock valued at $7,259,000 after buying an additional 306,330 shares in the last quarter. Trexquant Investment LP purchased a new position in Celldex Therapeutics in the 1st quarter valued at approximately $1,420,000. GSA Capital Partners LLP purchased a new stake in Celldex Therapeutics during the first quarter worth $1,131,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Celldex Therapeutics in the second quarter valued at $1,188,000.

Celldex Therapeutics Stock Performance

Shares of CLDX opened at $24.25 on Thursday. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -8.06 and a beta of 1.36. The stock’s fifty day moving average is $25.49 and its 200-day moving average is $22.82. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $29.05.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. Analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on CLDX. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $62.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, September 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, October 8th. HC Wainwright decreased their price target on shares of Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating for the company in a research report on Wednesday, August 20th. Citigroup lowered their price objective on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating for the company in a research report on Wednesday, August 20th. Finally, Barclays cut their target price on Celldex Therapeutics from $25.00 to $21.00 and set an “underweight” rating on the stock in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.80.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.